Molecular Partners Names MP0730 Lead CD70 Radio-DARPin

The company said MP0730 is the third program in its radiotherapeutics pipeline, with a first-in-human study expected to start in mid-2027. Preclinical data showed strong and sustained tumor uptake in mice.